In order to focus our analysis on patients with high-risk, HER2-positive breast cancer, our analysis was limited to the 253 patients (73.1%) with tumor stage ≥ T2 or node-positive disease at diagnosis. This evidence concerns the gene ERBB2 and breast carcinoma.